Biomarker for cancer diagnosis and use thereof
AssigneeInnobation Bio Co., Ltd.
InventorsSeung Koo KIM, Ki Tae KIM
Life of this patent
Estimating the term…
Loading patent…
AssigneeInnobation Bio Co., Ltd.
InventorsSeung Koo KIM, Ki Tae KIM
Estimating the term…
The present invention relates to biomarkers for cancer diagnosis and uses thereof, and more particularly to a composition for diagnosing or predicting cancer prognosis, comprising an agent for measuring levels of at least one biomarker selected from the group consisting of Complement Component 7 (C7), Dodecanoyl-L-carnitine (DC), Lysophosphatidylcholine (LPC), Histidine-Rich Glycoprotein (HRG) and Osteopontin in blood, and a method of using the biomarker to provide information about the diagnosis or prognosis of cancer. In the present invention, it was confirmed that the level of complement component 7 (C7), dodecanoyl-L-carnitine (DC), lysophosphatidylcholine (LPC), histidine-rich glycoprotein (HRG), and/or osteopontin (OPN) in blood of lung and/or hepatic cancer patients has been found to have different patterns than that of normal individuals, and the combination of these markers has been shown to improve the diagnosis of various cancers, including lung or hepatic cancer. Accordingly, the biomarkers of the present invention can be useful in cancer diagnosis and prognosis.
A biomarker composition for diagnosing cancer, wherein the composition comprises at least one biomarker selected from the group consisting of Complement Component 7 (C7), Dodecanoyl-L-carnitine (DC), Lysophosphatidylcholine (LPC), Histidine-Rich Glycoprotein (HRG), and Osteopontin (OPN), and wherein the biomarker is derived from blood.
A method of providing information for diagnosing cancer, comprising
Dependencies are inferred from the claim text.